Valuation: AbbVie

Market Cap 442B 387B 357B 330B 625B 42,110B 635B 4,261B 1,671B 20,742B 1,658B 1,622B 71,385B P/E 2026 *
30.2x
P/E 2027 * 23.5x
Enterprise Value 497B 435B 401B 371B 703B 47,355B 714B 4,792B 1,879B 23,326B 1,864B 1,824B 80,277B EV / Sales 2026 *
7.39x
EV / Sales 2027 * 6.71x
Free-Float
95.71%
Yield 2026 *
2.74%
Yield 2027 * 2.89%
Manager TitleAgeSince
Chief Executive Officer 55 30/06/2024
Director of Finance/CFO 59 22/06/2022
Chief Tech/Sci/R&D Officer - 29/02/2024
Director TitleAgeSince
Director/Board Member 65 31/12/2012
Director/Board Member 74 31/12/2012
Director/Board Member 68 31/12/2012
Change 5-day change 1-year change 3-year change Capi.($)
-8.07%-3.48% - - 442B
-2.33%-2.09%+50.33%+162.29% 1,085B
-0.82%-2.30%+62.97%+61.11% 624B
+0.33%-1.17%+27.98%+26.90% 332B
-0.02%-2.85%+25.27%+44.88% 282B
-3.89%-11.22%+20.78%+26.07% 277B
+0.66%-1.42%-29.26%-39.30% 217B
-0.06%-2.88%+20.98%+61.70% 196B
-3.72%-1.10%+13.35%+71.53% 167B
-0.33%-0.62%-6.25%-32.26% 138B
Average -1.47%-1.42%+20.68%+42.55% 368.73B
Weighted average by Cap. -1.37%-0.60%+34.72%+76.58%

Financials

2026 *2027 *
Net sales 67.23B 58.9B 54.31B 50.18B 95.14B 6,411B 96.73B 649B 254B 3,158B 252B 247B 10,869B 72.73B 63.72B 58.75B 54.29B 103B 6,936B 105B 702B 275B 3,417B 273B 267B 11,758B
Net income 14.35B 12.57B 11.59B 10.71B 20.31B 1,369B 20.65B 139B 54.33B 674B 53.89B 52.72B 2,320B 19.02B 16.67B 15.37B 14.2B 26.92B 1,814B 27.37B 184B 72B 894B 71.42B 69.87B 3,076B
Net Debt 55B 48.19B 44.43B 41.06B 77.84B 5,246B 79.14B 531B 208B 2,584B 206B 202B 8,893B 46.43B 40.68B 37.5B 34.65B 65.7B 4,428B 66.8B 448B 176B 2,181B 174B 171B 7,506B
Logo AbbVie
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
-
Trader
Investor
Global
Quality
-
ESG MSCI
AA